-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivatives更多Trade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo Clearing更多Euronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in Europe更多Euronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)更多The new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indices更多The first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Regulation
-
About Euronext
-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivatives更多Trade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo Clearing更多Euronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in Europe更多Euronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)更多The new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indices更多The first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Regulation
-
About Euronext
EnterNext welcomes OSE Pharma on Euronext in Paris
30/03/2015
Dominique Costantini, co-founder et CEO of OSE Pharma, rings the closing bell.
OSE Pharma is a biotechnology group that specializes in the research and development of therapeutic products for the treatment of cancers and lung disease.
At the end of 2013, the group had a portfolio of 5 products in development phase, including 4 in phase II (colon, breast and ovarian cancer, and cystic fibrosis) and 1 in phase III (lung cancer).